Evidence map›Paper›PMID 26009596›Full record

ReviewEuropean heart journal2015

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Albert Wiegman, Samuel S Gidding, Gerald F Watts, M John Chapman, Henry N Ginsberg, Marina Cuchel, Leiv Ose, Maurizio Averna, Catherine Boileau, Jan Borén and 23 more

3 registry-linked trialsOpen access · greenAbstract readReviewConsensus Statement
In one paragraph

Review in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 324 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
324citing papers in PubMed, 7 pooled it
74.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04458766 nacompletednot on this mapstarted 2021, after this paper: background citation

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence to Statins in Adolescents With Familial Hypercholesterolemia

TypeinterventionalSponsorBoston Children's HospitalRan2021 to 2024Enrolled11ConditionsFamilial Hypercholesterolemia, Adherence, MedicationArmsMonetary incentives
NCT04507984 completednot on this mapstarted 2019, after this paper: background citation

Universal Screening for Familial Hypercholesterolemia in Children - a Practical Approach

Typeobservational_patient_registrySponsorUniversity of Ljubljana, Faculty of MedicineRan2019 to 2021Enrolled17,000ConditionsFamilial Hypercholesterolemia, Polygenic HypercholesterolaemiaArmsGenetic analysis, Lipid levels measurement
NCT05124847 nacompletednot on this mapstarted 2021, after this paper: background citation

Time Restricted Eating as a Treatment for Pediatric Obesity

TypeinterventionalSponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludRan2021 to 2023Enrolled30ConditionsInfant Obesity, Hepatic Steatosis, Metabolic Syndrome, Insulin ResistanceArmsStandard Care, Time restricted eating
3 · Its place in the literature

Who cites it

324 citing papers in PubMed, 7 syntheses or guidelines pooled it, 846 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Familial hypercholesterolemia - treatment update in children, systematic review.Pediatric endocrinology, diabetes, and metabolism · 2022
    Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Putative protective role ofAtherosclerosis plus · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

264 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 13 countries.

Albert WiegmanDepartment of Paediatrics, Academic Medical Center, University of Amsterdam, The Netherlands a.wiegman@amc.uva.nl.
Samuel S GiddingNemours Cardiac Center, A. I. DuPont Hospital for Children, Wilmington, DE, USA.
Gerald F WattsSchool of Medicine and Pharmacology, Royal Perth Hospital Unit, The University of Western Australia, Western Australia, Australia.
M John ChapmanPierre and Marie Curie University, Paris, France National Institute for Health and Medical Research (INSERM), Pitié-Salpêtrière University Hospital, Paris, France.
Henry N GinsbergColumbia University College of Physicians and Surgeons, New York, NY, USA Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, USA.
Marina CuchelPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Leiv OseDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway Lipid Clinic, Oslo University Hospital, Oslo, Norway.
Maurizio AvernaDepartment of Internal Medicine, University of Palermo, Italy.
Catherine BoileauDiderot Medical School, University Paris 7, Paris, France Genetics Department, Bichat University Hospital, Paris, France INSERM U698, Paris, France.
Jan BorénDepartment of Medicine, Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden Wallenberg Laboratory for Cardiovascular Research, Gothenburg, Sweden.
Eric BruckertDepartment of Endocrinology and Prevention of Cardiovascular Disease, University Hospital Pitié-Salpêtrière, Paris, France.
Alberico L CatapanoDepartment of Pharmacology, Faculty of Pharmacy, University of Milano, Milan, Italy Multimedica IRCSS, Milan, Italy.
Joep C DefescheDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.
Olivier S DescampsCentre Hospitalier Jolimont-Lobbes, Nivelles-Tubize, Belgium.
Robert A HegeleRobarts Research Institute, University of Western Ontario, London, ON, Canada.
G Kees HovinghDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.
Steve E HumphriesCentre for Cardiovascular Genetics, University College London, Institute of Cardiovascular Sciences, London, UK.
Petri T KovanenWihuri Research Institute, Helsinki, Finland.
Jan Albert KuivenhovenDepartment of Pediatrics, Section Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Luis MasanaVascular Medicine and Metabolic Unit, Department of Medicine and Surgery, University Rovira and Virgili, Reus-Tarragona, Spain.
Børge G NordestgaardDepartment of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Päivi PajukantaDepartment of Human Genetics, Center for Metabolic Disease Prevention, University of California, Los Angeles, USA.
Klaus G ParhoferDepartment of Endocrinology and Metabolism, University of Munich, Munich, Germany.
Frederick J RaalCarbohydrate & Lipid Metabolism Research Unit; and Division of Endocrinology & Metabolism, University of the Witwatersrand, Johannesburg, South Africa.
Kausik K RayDepartment of Primary Care and Public Health, School of Public Health, Imperial College, London, UK.
Raul D SantosLipid Clinic of the Heart Institute (InCor), University of São Paulo, São Paulo, Brazil Department of Cardiology, University of São Paulo Medical School, São Paulo, Brazil.
Anton F H StalenhoefDepartment of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Elisabeth Steinhagen-ThiessenEvangelisches Geriatriezentrum Berlin gGmbH (EGZB), Berlin, Germany Charité - Universitätsmedizin, Berlin, Germany.
Erik S StroesDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.
Marja-Riitta TaskinenResearch Programs Unit, Diabetes & Obesity, University of Helsinki and Heart & Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Anne Tybjærg-HansenDepartment of Clinical Biochemistry, Section for Molecular Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Olov WiklundDepartment of Experimental and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
European Atherosclerosis Society Consensus Panel
Amsterdam UMC Location University of Amsterdam · NLUniversity of Copenhagen · DKDuPont (United States) · USHôpital de Jolimont · BEImperial College London · GBInserm · FRLudwig-Maximilians-Universität München · DERadboud University Nijmegen · NLThe University of Western Australia · AUUniversitat Rovira i Virgili · ESUniversity College London · GBUniversity Medical Center Groningen · NLUniversity of Amsterdam · NLUniversity of California, Los Angeles · USUniversity of Helsinki · FIUniversity of Palermo · ITUniversity of Pennsylvania · USUniversity of the Witwatersrand · ZAWestern University · CAWihuri Research Institute · FI

Funding

Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 1985 to 2019
$50.2M
Genomics of dyslipidemia in MexicansR01HL095056 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJUKANTA, PAIVI · 2009 to 2018
$5.9M
British Heart Foundation RG/08/008/25291NHLBI NIH HHS P01 HL028481NHLBI NIH HHS R01 HL095056
6 · The paper itself

Abstract

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testing. Childhood is the optimal period for discrimination between FH and non-FH using LDL-C screening. An LDL-C ≥5 mmol/L (190 mg/dL), or an LDL-C ≥4 mmol/L (160 mg/dL) with family history of premature CHD and/or high baseline cholesterol in one parent, make the phenotypic diagnosis. If a parent has a genetic defect, the LDL-C cut-off for the child is ≥3.5 mmol/L (130 mg/dL). We recommend cascade screening of families using a combined phenotypic and genotypic strategy. In children, testing is recommended from age 5 years, or earlier if homozygous FH is suspected. A healthy lifestyle and statin treatment (from age 8 to 10 years) are the cornerstones of management of heterozygous FH. Target LDL-C is <3.5 mmol/L (130 mg/dL) if >10 years, or ideally 50% reduction from baseline if 8-10 years, especially with very high LDL-C, elevated lipoprotein(a), a family history of premature CHD or other cardiovascular risk factors, balanced against the long-term risk of treatment side effects. Identifying FH early and optimally lowering LDL-C over the lifespan reduces cumulative LDL-C burden and offers health and socioeconomic benefits. To drive policy change for timely detection and management, we call for further studies in the young. Increased awareness, early identification, and optimal treatment from childhood are critical to adding decades of healthy life for children and adolescents with FH.

Indexed as

AdolescentAdultAtherosclerosisCarotid Intima-Media ThicknessChildClinical Laboratory TechniquesCost of IllnessCounselingDietDietary SupplementsEarly DiagnosisEconomics, MedicalEvidence-Based MedicineFemaleGenetic TestingHeterozygoteAdolescentsChildrenConsensus statementDiagnosisEzetimibeFamilial hypercholesterolaemiaLDL cholesterolPCSK9 inhibitorStatinTreatment

Identifiers

PMID26009596
PMCPMC4576143
OpenAlexW2104299102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.